Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6% HES 130/0.4 vs 6% HES 70/0.5 in Orthopedic Surgery
NCT01010022Phase 3Completed
- Sponsor
- Fresenius
- Start
- Nov 2009
- Primary completion
- Jul 2010
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetastarch in hypovolemia, sponsored by Fresenius. Started Nov 2009; status: completed.
02
Drugs
hetastarch
03
Conditions
hypovolemia
Beyond the preview
Go deeper on NCT01010022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010022.